Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Big Bull Michael Saylor Gives Another Bitcoin (BTC) Signal For The New Week

Big Bull Michael Saylor Gives Another Bitcoin (BTC) Signal For The New Week

CryptoNewsNetCryptoNewsNet2025/11/03 06:36
By:en.bitcoinsistemi.com

MicroStrategy founder Michael Saylor has once again shared Saylor Tracker data, raising expectations that a new Bitcoin (BTC) purchase may be on the agenda.

Saylor shared the phrase “November's color is orange” on the X platform. This statement was linked to the large Bitcoin purchases that followed similar posts in the past.

Historical data shows that MicroStrategy typically announces new acquisitions within days of such “Saylor Tracker” announcements. A new BTC acquisition announcement could be made tomorrow.

As of November 2, 2025, MicroStrategy's Bitcoin portfolio reached 640,808 BTC. The company's total BTC holdings stood at $70.7 billion. With an average purchase price of $74,032, the portfolio represents a 49.03% profit at current market prices, representing an unrealized gain of $23.25 billion.

MicroStrategy's year-to-date Bitcoin return is calculated at 26.21%. Furthermore, the company's “sats per share” (Satoshi per share) has improved significantly compared to last year. Conversely, while the price of Bitcoin has risen by 60.5% in the past year, MicroStrategy shares have only gained 17.33%. This represents a performance difference of approximately 43 percentage points compared to Bitcoin.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

RNA therapy company Adarx Pharmaceuticals (ADRX.US) plans to raise up to $372 million in a U.S. IPO; pharmaceutical giant AbbVie (ABBV.US) has agreed to invest up to $100 million

RNA therapy company Adarx Pharmaceuticals, which is in the late stage of clinical development, plans to raise up to $371.9 million through its initial public offering (IPO) in the United States.

智通财经2026/09/21 16:16